These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 20530276)

  • 21. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
    J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
    Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
    J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
    Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
    Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Egerton N
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
    Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
    Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.
    Li L; Li J; Yang K; Tian J; Sun T; Jia W; Zhang P; Yi K
    Future Oncol; 2010 Feb; 6(2):201-7. PubMed ID: 20146579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
    Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
    Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
    Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
    J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
    Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA
    Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
    Castaneda CA; Gómez HL
    Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.